MELANIE HOPKINS: Open Payments
NPI 1528060845 · LISBON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,237 in 65 payments from 11 companies in 2025. Trend: 2023 $1,344 · 2024 $1,465 · 2025 $1,237
Food & beverage: $1,237
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $327 |
| ABBVIE INC. | 17 | $238 |
| GlaxoSmithKline, LLC. | 6 | $160 |
| Phathom Pharmaceuticals, Inc. | 8 | $154 |
| Lundbeck LLC | 3 | $80 |
| Amgen Inc. | 4 | $66 |
| PFIZER INC. | 3 | $61 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $34 |
Products named: Rybelsus, Ozempic, VOQUEZNA, VRAYLAR, REXULTI, UBRELVY, TRELEGY ELLIPTA, AREXVY.
Industry payments across CT — which companies pay providers there.
